The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Pharmaceutical Research Année : 2011

The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors

Laurent Guilleminault
Brigitte Legrain
  • Fonction : Auteur
Dominique-Henri Douvin
  • Fonction : Auteur
Hervé Watier
Nathalie Heuzé-Vourc'H

Résumé

Lung cancer is the leading cause of cancer-related death worldwide. The efficacy of current systemic treatments is limited, with major side effects and only modest survival improvements. Aerosols routinely used to deliver drugs into the lung for treating infectious and inflammatory lung diseases have never been used to deliver monoclonal antibodies to treat lung cancer. We have shown that cetuximab, a chimeric anticancer anti-EGFR mAb, is suitable for airway delivery as it resists the physical constraints of aerosolization, and have evaluated the aerosol delivery of cetuximab in vivo.

Domaines

Cancer Médicaments

Dates et versions

hal-01769936 , version 1 (18-04-2018)

Identifiants

Citer

Agnes Maillet, Laurent Guilleminault, Etienne Lemarié, Stephanie Lerondel, Nicolas Azzopardi, et al.. The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. Pharmaceutical Research, 2011, 28 (9), pp.2147 - 2156. ⟨10.1007/s11095-011-0442-5⟩. ⟨hal-01769936⟩
81 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More